Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.69 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.62 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.62 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786882 | 0.88 | KCNK3 (0.87) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL3674558 | 0.88 | KCNK3 (0.71) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL9067770 | 0.88 | KMT2A (1.00) | MEN1KMT2AKCNK3KCNK9KDM4E | |
| SCHEMBL1811760 | 0.87 | KCNK3 (0.79) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL2058359 | 0.86 | KMT2A (0.96) | MEN1KMT2AKCNK3KCNK9KDM4E | |
| Hydrochloric Acid SCHEMBL2107467 | 0.86 | KCNK3 (0.77) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL1459180 | 0.85 | MEN1 (0.64) | MEN1KMT2AFFAR1 | |
| SCHEMBL8363018 | 0.84 | SMN1; SMN2 (0.76) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL3454686 | 0.84 | MEN1 (0.65) | MEN1KMT2AKCNK3KCNK9MAPT | |
| SCHEMBL2565385 | 0.84 | TP53 (0.78) | MEN1KMT2AKCNK3KCNK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | MEN1 694/4885KMT2A 2408/4885KCNK3 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.